aTyr Pharma Inc. (NASDAQ:LIFE) Q1 2020 Earnings Conference Call - Final Transcript

May 12, 2020 • 05:00 pm ET


aTyr Pharma Inc. (NASDAQ:LIFE) Q1 2020 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Good afternoon, ladies and gentlemen. Welcome to the aTyr Pharma First Quarter 2020 Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, this conference is being recorded for replay purposes. It is now my pleasure to hand the conference over to Ms. Jill Broadfoot, aTyr's Chief Financial Officer. Ms Broadfoot, you may begin.

Jill Broadfoot

Thank you, and good afternoon, everyone. Thank you for joining us today to discuss aTyr's first quarter operating results and corporate

Update.We are joined today by Dr. Sanjay Shukla, our President and CEO. On the call, Sanjay will provide an update on our corporate strategy, including the clinical development of ATYR1923 and our research program in Neuropilin-2 or NRP2 and tRNA synthetase biology. I will then review the financial results and our current financial positioning before handing it back to Sanjay to open the call up for any questions. Before we begin, I would like to remind everyone that except for statements of historical fact, the statements made by management and responses to questions on this conference call are forward-looking statements under the safe harbor provision of the Private Securities Litigation Reform Act of 1995.

These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Please see the forward-looking statement disclaimer in the Company's press release issued this afternoon as well as the risk factors in the Company's SEC filings and included in our most recent annual report on Form 10-K and quarterly reports on Form 10-Q. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, as facts and circumstances underlying these forward-looking statements may change. Except as required by law, aTyr Pharma disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances. I will now turn the call over to Sanjay.

Sanjay Shukla

Good afternoon, everyone, And thank you for joining us for our first quarter 2020 results conference call. Before we begin, I would like to say on behalf of aTyr and our employees that we stand in support of all of our healthcare providers, essential personnel, partners, patients and community as we continue to work through the ongoing COVID-19 pandemic. We acted accordingly to implement a plan to ensure the safety of everyone involved with our clinical and research programs, while minimizing disruption to our business operation.

We continue to abide by government directives and operate our business remotely in order to play our role in minimizing the spread of the virus to our employees and their families and ease the burden on our healthcare system. Now let's get started with our quarterly review and corporate update. During the first quarter of 2020 and subsequent period, aTyr progressed the development of our clinical program for ATYR1923 including entering in major collaboration for expanded development and announcing a new trial in COVID-19 patients. We also advanced our pipeline of discovery programs and strengthened our balance